Call Now

Mouse TNFRSF4 / OX40 / CD134 Protein (Fc Tag)

ACT35,CD134,Ly-70,Ox40,Txgp1,TXGP1L

Catalog Number P50808-M02H
Organism Species Mouse
Host Human Cells
Synonyms ACT35,CD134,Ly-70,Ox40,Txgp1,TXGP1L
Molecular Weight The recombinant mouse TNFRSF4/Fc is a disulfide-linked homodimer. The reduced monomer comprises 433 amino acids and has a calculated molecular mass of 48.3 kDa. As a result of glycosylation, the apparent molecular mass of the monomer is approximately 60 kDa in SDS-PAGE under reducing conditions.
predicted N Val 20
SDS-PAGE
Purity > 92 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the extracellular domain of mouse TNFRSF4 (P47741) (Met 1-Pro 211) was fused with the Fc region of human IgG1 at the C-terminus.
Bio-activity
Research Area Immunology |Cluster of Differentiation (CD) |B Cell CD Antigen
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.
Reference
  • Compaan D.M., et al. (2006) .The crystal structure of the costimulatory OX40-OX40L complex. Structure 14:1321-1330.
  • Kawamata S., et al. (1998) .Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J. Biol. Chem. 273:5808-5814.
  • Byun M., (2013) Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J. Exp. Med. 210:1743-1759.